SIONNA THERAPEUTICS
Redefining What’s Possible in Cystic Fibrosis Treatment
A mission to fully restore CFTR function for people living with cystic fibrosis
Cystic fibrosis (CF) is a serious, potentially fatal inherited disease resulting from mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which encodes an ion channel protein that helps regulate the flow of chloride ions and water in and out of epithelial cells lining the lungs, pancreas and other organs.
These CFTR mutations prevent the protein from functioning normally and ultimately lead to a buildup of mucus in the lungs and airways, impaired pancreatic secretion and other aspects of CF pathology that compromise patient health.
Stabilizing the Unstable
With the goal of fully normalizing CFTR function, Sionna is creating therapies that stabilize NBD1, the key mechanism that current CF modulator therapies lack.
We partnered with Ten Bridge Communications to create a series of animated segments that visualize the effect effect Sionna’s small molecule therapies have on stabilizing NBD1.
Let’s Get Started.
Want to discuss your next project, or just get some further information? We'd love to chat.